A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT01496742. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Metmab Vs. Placebo in Combination With Either Bevacizumab + Platinum + Paclitaxel or Pemetrexed + Platinum in Patients With Untreated Stage IIIb or IV Non-Squamous NSCLC
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of RO5490258 (MetMab) in combination with either of two backbone chemotherapy regimens in the first-line setting in patients with incurable Stage IIIB or IV non-squamous non-small cell lung cancer. In Cohort 1, patients will be randomized to receive 4 cycles of bevacizumab (Avastin) 15 mg/kg iv, paclitaxel 200 mg/m2 iv, platinum (cisplatin/carboplatin) iv plus either MetMab 15 mg/kg iv or placebo on Day 1 of each 21-day cycle. In Cohort 2, patients will be randomized to receive pemetrexed 500 mg/m2 iv, platinum (cisplatin/carboplatin) iv plus either MetMAb 15 mg/m2 iv or placebo on Day 1 of each 21-day cycle. Patients who have not progressed after 4 cycles will be offered maintenance therapy with their assigned treatment of bevacizumab plus either MetMAb or placebo (Cohort 1) or pemetrexed plus either MetMAb or placebo (Cohort 2). Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.
Study identification
- NCT ID
- NCT01496742
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 259 participants
Conditions and interventions
Conditions
Interventions
- Placebo Drug
- RO5490258 Drug
- bevacizumab [Avastin] Drug
- cisplatin/carboplatin Drug
- paclitaxel Drug
- pemetrexed Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2012
- Primary completion
- Oct 31, 2015
- Completion
- Oct 31, 2015
- Last update posted
- Sep 22, 2016
2012 – 2015
United States locations
- U.S. sites
- 32
- U.S. states
- 16
- U.S. cities
- 30
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Huntsville | Alabama | 35805 | — |
| Not listed | Scottsdale | Arizona | 85259 | — |
| Not listed | Bakersfield | California | 93309 | — |
| Not listed | Fullerton | California | 92835 | — |
| Not listed | Los Angeles | California | 90024 | — |
| Not listed | Los Angeles | California | 90095-1772 | — |
| Not listed | Northridge | California | 91328 | — |
| Not listed | San Luis Obispo | California | 93454 | — |
| Not listed | Santa Barbara | California | 93105 | — |
| Not listed | Stanford | California | 94305-5820 | — |
| Not listed | Grand Junction | Colorado | 81502-1628 | — |
| Not listed | Boynton Beach | Florida | 33435 | — |
| Not listed | Hollywood | Florida | 33021 | — |
| Not listed | Orlando | Florida | 32804 | — |
| Not listed | Lawrenceville | Georgia | 30045 | — |
| Not listed | Marietta | Georgia | 30060 | — |
| Not listed | Harvey | Illinois | 60426 | — |
| Not listed | Fort Wayne | Indiana | 46815 | — |
| Not listed | Fort Wayne | Indiana | 46845 | — |
| Not listed | Indianapolis | Indiana | 46260 | — |
| Not listed | Muncie | Indiana | 47303 | — |
| Not listed | Metairie | Louisiana | 70006 | — |
| Not listed | Minneapolis | Minnesota | 55454 | — |
| Not listed | Las Vegas | Nevada | 89148 | — |
| Not listed | New York | New York | 10016 | — |
| Not listed | Hickory | North Carolina | 28602 | — |
| Not listed | Cleveland | Ohio | 44195 | — |
| Not listed | Columbus | Ohio | 43215 | — |
| Not listed | Middletown | Ohio | 45042 | — |
| Not listed | Bend | Oregon | 97701 | — |
| Not listed | Portland | Oregon | 97239 | — |
| Not listed | Seattle | Washington | 98195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 55 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01496742, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 22, 2016 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01496742 live on ClinicalTrials.gov.